The Food and Drug Administration approved AstraZeneca's Baxfendy on May 18, 2026, making baxdrostat the first medicine in a genuinely new class for high blood pressure in decades. The drug is a once-daily tablet meant for adults whose blood pressure is not controlled by their current medications, and it works by shutting down a hormone called aldosterone that quietly drives up pressure in some patients.
Aldosterone tells the body to hold on to salt and water while pushing out potassium, and too much of it stiffens the numbers on the cuff. Baxdrostat blocks the enzyme that produces the hormone in the first place, a pathway that ACE inhibitors, ARBs, beta blockers, and calcium channel blockers do not target directly.
What the pivotal trial actually showed
The approval rests on the BaxHTN Phase 3 trial, a 12-week study published in August 2025 in the New England Journal of Medicine. Patients were already on stable therapy, either two medications for uncontrolled hypertension or three or more plus a diuretic for resistant hypertension.
At week 12, seated systolic blood pressure fell by 15.7 mm Hg in patients on the 2 mg dose and by 14.5 mm Hg on the 1 mg dose, compared with a 5.8 mm Hg drop on placebo. That is a placebo-corrected reduction of 9.8 and 8.7 mm Hg, and both doses hit the primary endpoint with statistical significance.
Also read: NAD+ boosters are everywhere - but what do human trials actually show?
The trial was presented at the European Society of Cardiology congress and simultaneously published in NEJM. Bryan Williams, chair of medicine at University College London and the primary investigator, called the mechanism a way to target "a root cause of persistently uncontrolled hypertension," according to reporting by BioPharma Dive.
Who the drug is for, and the safety trade-off
Baxfendy is cleared as an add-on treatment for adults whose blood pressure is not adequately controlled on other antihypertensive drugs, the American College of Cardiology confirmed after the approval. It is not a first-line pill, and it is not a replacement for lifestyle changes or existing therapy.
The safety trade-off is real and specific. Because baxdrostat lowers aldosterone, potassium can rise. In the trial, a potassium level above 6.0 mmol per liter, a threshold that can affect the heart, was reported in 2.3 percent of patients on the 1 mg dose and 3.0 percent on the 2 mg dose, versus 0.4 percent on placebo.
Muscle spasms, dizziness, and low blood pressure were also more common than with placebo. That matters because the same patients most likely to benefit, those on multiple drugs including diuretics, are also the most likely to have shifting electrolytes. Anyone whose blood pressure is not well controlled on their current regimen should talk to their doctor about whether a new class of medication fits their situation, and about the monitoring that would come with it.
Also read: MMR is being split into 3 shots by executive order. Here is what the science shows
Why a new class matters at all
High blood pressure is not a small problem. Nearly half of American adults have hypertension, according to the CDC, and only about one in five has it under control. Millions of US adults stay elevated despite taking two or more standard medications, a group that has had no genuinely new mechanism to reach for in years.
Baxdrostat does not replace what already works. It adds a pathway that older drugs miss, aimed at the smaller but stubborn slice of patients whose blood pressure will not come down.
Also read: Losing 80 minutes of sleep caused weight gain, and it wasn't from eating more